Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Porntep Siriwanarangsun1
1Faculty of Medicine, Western University, Pathumtani Province, Thailand 210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand 3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.
Received: March 03, 2023; Published: April 01, 2023
Currently, in cancer or lung-cancer patients, immune checkpoint inhibitors (ICIs), such as anti-CTLA-4, anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1) antibodies, etc. are widely prescribed as single agent or in combination with other anticancer- treatment modalities [1]. Due to immune-associated adverse events (iaAEs), these ICIs can facilitate antitumor effects, such as interstitial pneumonitis, endocrine-gland-disorders-associated abnormal hormone secretion [2] that can be caused and aggravated by mRNA-based-COVID-19 vaccines (Figure 1) [1,3].
Citation: Attapon Cheepsattayakorn., et al. “Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Safety and Immunogenicity of mRNA-COVID-19 Vaccination". Acta Scientific Microbiology 6.5 (2023): 01-02.
Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.